Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment

Cancer Treatment Reviews

Volumn 22, Issue 4, 1996, Pages 289-331

  Vinholes, Jeferson ^a   Coleman, Robert ^a   Eastell, Richard ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; HYDROXYLYSINE; HYDROXYPROLINE; MEGESTROL ACETATE; MELPHALAN; OSTEOCALCIN; PAMIDRONIC ACID; PEPTIDE; PREDNISOLONE; PROCOLLAGEN; PYRIDINOLINE; TAMOXIFEN;

BONE METABOLISM; BONE METASTASIS; BONE MINERAL; BONE REMODELING; BONE SCINTISCANNING; CALCIUM URINE LEVEL; CANCER; CANCER SURVIVAL; CANCER THERAPY; CIRCADIAN RHYTHM; COLLAGEN DEGRADATION; COMPUTER ASSISTED TOMOGRAPHY; CORTICAL BONE; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PATIENT MONITORING; RADIOGRAPHY; RADIOIMMUNOASSAY; REVIEW; TRABECULAR BONE; URINALYSIS; X RAY ANALYSIS;

EID: 0030455389     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(96)90021-3     Document Type: Article

References (248)

1. Coleman, R. & Rubens, R. (1987a) The clinical course of bone metastases from breast cancer. Br. J. Cancer 55: 61-66.
2. Hortobagyi, G. (1991) Bone metastases in breast cancer patients. Semin. Oncol. 18 (Suppl. 5): 11-15.
3. Hanks, G. E., Myers, C. E. & Scardino, P. T. (1993) Cancer of the prostate. In: DeVita, V., Hellman, S. & Rosenberg, S.A., eds, Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott Company, pp. 1073-1113.
4. Abrams, J., Doyle, L. A. & Aisner, J. (1988) Staging, prognostic features and special considerations in small cell lung cancer. Semin. Oncol. 15: 261-277.
5. Nesbit, R. M. & Baum, W. C. (1984) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. J. Natl. Can. Inst. 68: 507-517.
6. Bross, P., Reynders, P. & Vanderschot, P. (1993) Surgical treatment of the metastatic fracture of the femur improves quality of life. Acta Orthop. Belg. 59 (Suppl. 1): 52-56.
7. Kivirikko K. I. & Ristelli, L. (1976) Biosynthesis of collagen and its alterations in pathological states. Med. Biol. 54: 159-186.
8. Prockop, D. J., Kivirikko, K. I., Guzman, N. A. et al. (1979) The biosynthesis of collagen and its disorders. N. Engl. J. Med. 301: 13-23.
9. Kivirikko, K. I. & Myllyla, R. (1985) Post-translational processing of procollagens. Ann. NY Acad. Sci. 460: 187-201.
10. Hulmes D. J. S. & Miller, A. (1979) Quasi-hexagonal molecular packing in collagen fibrils. Nature 282: 878-880.
11. Fujimoto, D. (1977) Isolation and characterisation of a fluorescent material in bovine achilles tendon collagen. Biochem. Biophys. Res. Commun. 76: 1124-1129.
12. Fujimoto, D. & Moriguchi, T. (1978) Pyridinoline, a non-reducible cross-link of collagen. J. Biochem. 83: 863-867.
13. Ogawa, T., Ono, T., Kawanishi, Y. (1982) A novel fluor in insoluble collagen: a cross-linking moiety in collagen molecule. Biochem. Biophys. Res. Commun. 107: 1252-1257.
14. Robins, S. P., Bailey, A. J. (1975) The chemistry of the collagen cross-links: the mechanism of stabilisation of the reducible intermediate cross-links. Biochem. J. 149: 381-385.
15. Eyre, D. R., Paz, M. A. & Gallop, P. M. (1984) Cross-linking in collagen and elastin. Ann. Rev. Biochem. 53: 717-748.
16. Robins, S. P. & Duncan, A. (1983) Crosslinking of collagen: location of pyridinoline in bovine articular cartilage at two sites of the molecule. Biochem. J. 215: 175-182.
17. Mechanic, G. L., Katz, E. P., Noyes, C. et al. (1987) Locus of a histidine based, stable trifunctional, helix to helix collagen cross-link: stereospecific collagen structure of type I skin fibrils. Biochem. 26: 3500-3569.
18. Vaes, G. (1987) Cellular biology and biochemical mechanism of bone resorption. Clin. Orthop. 231: 239-271.
19. Parfitt, A. M. (1983) The physiologic and clinical significance of bone histomorphometric data. In: Recker RR, ed., Bone Histomorphometry: Techniques and Interpretation. Boca Raton: CRC Press, pp. 143-223.
20. Manolagas, S. C. & Jilka, R. L. (1995) Bone marrow, cytokines and bone remodelling. N. Engl. J. Med. 332: 305-311.
21. Clarke, N. W., McClure, J. & George, N. J. R. (1992) Dissodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br. J. Urol. 69: 64-70.
22. Yoneda, T., Chavez, J. B., Mundy, G. R. et al. (1991) Evidence that tumour necrosis factor plays a pathogenic role in the paraneoplastic syndromes of cachexia, hypercalcaemia, and leukocytosis in a human tumour in nude mice. J. Clin. Invest. 87: 977-985.
23. Boyce, B. F. (1991) Normal bone remodelling and its disruption in metastatic bone disease. In: Rubens, R. D. & Fogelman, I., eds, Bone Metastases - Diagnosis and Treatment. London: Springer-Verlag, pp. 11-30.
24. Mundy, G. (1995) Metastatic bone disease. In: Mundy, G., ed., Bone Remodelling and its Disorders. London: Martin Dunitz, pp. 104-122.
25. Orr, F. W., Kostenuik, P., Singh, G. et al. (1995) Tumour-bone interactions in skeletal metastases. Clin. Orthop. Relat Res. 312: 19-33.
26. Hauschka, P. V. Mavrakos, A. E., Iafrati, M. D. et al. (1986) Growth factors in bone matrix. J. Biol. Chem. 261: 655-674.
27. Peacock, M., Robertson, W. D. & Nordin, B. E. C. (1969) Relation between serum and urinary calcium with particular reference to parathyroid activities. Lancet 22: 384-386.
28. Vinholes, J., Eastell, R., Coleman, R. et al. (1996a) Metabolic effects of pamidronate in patients with metastatic bone disease. Br. J. Cancer 73: 1089-1095.
29. Pecherstorfer, M., Ludwig, H., Zimmer-Roth, J. et al. (1995) The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J. Clin. Endocrinol. Metab. 80: 97-103.
30. Berruti, A., Panero, A., Angelli, A. et al. (1996) Different mechanisms underlying bone collagen resorption in patients with bone metastases from prostate and breast cancer. Br. J. Cancer 73: 1581-1587.
31. Lipton, A., Glover, D., Seaman, J. et al. (1994) Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann. Oncology 5 (Suppl. 7): 31-35.
32. Vinholes, J., Eastell, R. & Coleman, R. (1996b) Randomised double-blind comparison of pamidrone or clodronate for hypercalcaemia of malignancy: effects on bone metabolism markers. J. Clin. Oncol. (in press).
33. Body, J. J., Piccart, M., Ford, J. et al. (1995a) Intravenous pamidronate in patients with tumour- induced osteolysis: a biochemical dose-response study. J. Bone Miner. Res. 10: 1191-1196.
34. Roux, C., Ravaud, P., Cohen-Solal, M. et al. (1994) Biologic, histologic and densitometric effects of oral residronate on bone in patients with multiple myeloma. Bone 15: 41-49.
35. Delmas, P. D., Vergnaud, P., Meunier, P. J. et al. (1991a) The in vivo anabolic effect of hPTH (1-34) is blunted when bone resorption is blocked by a bisphosphonate. J. Bone Miner. Res. 6 (Suppl. 1): 214.
36. Coleman, R. E., Whitaker, K. D., Moss, D. W., Mashiter, G., Fogelman, I. & Rubens, R. D. (1988a) Biochemical monitoring predicts response in bone to systemic treatment. Br. J. Cancer 58: 205-210.
37. Blomqvist, C., Elomaa, I., Risteli, J. et al. (1987) The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer 60: 2907-2912.
38. Deacon, A. C., Hulme, P., Reeve, J. et al. (1987) Estimation of whole body bone resorption rate: a comparison of urinary total hydroxyproline excretion with two radioisotopic tracer methods in osteoporosis. Clin. Chim. Acta. 166: 297-303.
39. Haddad, J. G., Cuoranz, S. & Avioli, L. V. (1970) Nondialysable urinary hydroxyproline as an index of bone collagen formation. J. Clin. Endocrinol. Metab. 30: 282-287.
40. Gasser, A., Celada, A., Wooton, R. et al. (1979) The clinical measurement of urinary total hydroxyproline excretion. Clin. Chim. Acta 95: 487-491.
41. Colwell, A., Russell, R. G. G. & Eastell, R. (1993) Factors affecting the assay of urinary 3- hydroxy pyridinium cross-links of collagen as markers of bone resorption. Eur. J. Clin Invest. 23: 341-349.
42. Mautalen, C. A. (1970) Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. J. Lab. Clin. Med. 75: 11-18.
43. Kivirikko, K., Laitinen, O. & Prockop, D. J. (1967) Modifications of a specific assay for hydroxyproline in urine. Anal. Biochem. 19: 249-255.
44. Podenphant, J., Larsen, N. E. & Christiansen, C. (1984) An easy and reliable method for determination of urinary hydroxyproline. Clin. Chim. Acta 142: 145-148.
45. Dawson, C., Jewel, S. & Driskell, W. (1988) Liquid Chromatographic determination of total hydroxyproline in urine. Clin. Chem. 34: 1572-1574.
46. Kontturi, M., Sontaniemi, E. & Larmi, T. (1974) Hydroxyproline in the early diagnosis of bone metastases in prostate cancer. Scand. J. Urol. Nephrol. 8: 91-95.
47. Bishop, M. C. & Fellows, G. J. (1977) Urine hydroxyproline excretion - a marker of bone metastases in prostatic carcinoma. Br. J. Urol. 49: 711-716.
48. Francini, G., Leone, V, Gennari, C. et al. (1988) Serum osteocalcin concentration in patients with prostate cancer. Am. J. Clin. Oncol. 11 (Suppl. 2) S83-87.
49. Myamoto, K. K., McSherry, S. A., Robins, S. P., Besterman, J. & Mohler, J. L. (1994) Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. The J. Urol. 151: 909-913.
50. Powles, T. J., Rosset, G. & Bondy, P. K. (1976) Early morning hydroxyproline excretion in patients with breast cancer. Cancer 38: 2564-2566.
51. Glover, D., Lipton, A., Macerata, R. S. et al. Intravenous pamidronate dissodium treatment of bone metastases in patients with breast cancer. Cancer 74: 2949-2955.
52. O'Rourke, N., McCloskey, E., Kanis, J. A. et al. (1995) Double-blind, placebo-controlled, dose- response trial of oral clodronate in patients with bone metastases. J. Clin. Oncol. 13: 929-934.
53. Coombes, R. C., Dady, P., Powles, J. et al. (1983) Assessment of response of bone metastases to systemic therapy. Cancer 52: 610-614.
54. Coleman, R. E., Fogelman, I. & Rubens, R. (1988b) Hypercalcaemia and breast cancer - an increased humoral component in patients with liver metastases. Eur. J. Surg. Oncol. 14: 423-428.
55. Body, J. J., Cleeren, A., Bijvoet, O. L. M. et al. (1986a) Treatment of malignancy-associated hypercalcaemia with intravenous aminohydroxypropylidine diphosphonate. J. Clin. Oncol. 4: 1177-1183.
56. Thiebaud, D., Jaeger, P. & Burckhardt, P. (1988) Dose-response in the treatment of hypercalcaemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J. Clin. Oncol. 6: 762-768.
57. Coleman, R. E. & Rubens, R. (1987b) 3 (amino-1, hydroxypropyledene) bisphosphonate (APD) for hypercalcaemia of breast cancer. Br. J. Cancer 56: 465-469.
58. Robins, S. P., Duncan, A. & Riggs, B. L. (1990) Direct measurement of free hydroxypyridinium cross-links of collagen in urine as new markers of bone resorption in osteoporosis. In: Christiansen, C. & Overgaad, K, eds, Osteoporosis. Copenhagen: Osteopress, pp. 465-468.
59. Anonymous (1992) Pyridinium cross-links as markers of bone resorption. Lancet 340: 278-279.
60. Robins, S. P., Woitge, H., Hesley, R. et al. (1994) Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9: 1643-1649.
61. Cosman, F., Nieves, J., Lindsay, R. et al. (1994) High-dose glucorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J. Bone Miner. Res. 9: 1097-1105.
62. Blumsohn, A., Naylor, K., Eastell, R. et al. (1995a) Effect of light and γ-irradiation on pyridinolines and telopeptides of type I collagen in urine. Clin. Chem. 41: 1195-1197.
63. Blumsohn, A., Hannon, R. A., Eastell, R. et al. (1994a) The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endoc. Metab. 79: 730-735.
64. Eastell, R., Russell, R. G., Riggs, B. L. et al. (1992) Nyctohemeral changes in bone turnover assessed by serum bone Gla protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing. Clin. Science 83: 375-382.
65. Schlemmer, A., Hassager, C., Christiansen, C. et al. (1992) Marked diurnal variation in urinary excretion of pyridinium cross-links in pre-menopausal women. J. Clin. Endocrinol. Metab. 74: 476-480.
66. Schlemmer, A., Hassager C., Christiansen, C. et al. (1994a) Posture, age, menopause and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium cross-links. J. Bone Miner. Res. 9: 1883-1888.
67. Panteghini, M. & Pagani, F. (1996) Biological variation in urinary excretion of pyridinium cross- links: recommendations for the optimum specimen. Ann. Clin. Biochem. 33: 36-42.
68. Blumsohn, A., Hannon, R. A., Eastell, R. et al. (1994b) Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. 40: 663-670.
69. Uebelhart, D., Gineyts, E., Delmas, P. D. et al. (1990) Urinary excretion of pyridinium cross- links: a new marker of bone resorption in metabolic bone disease. Bone Miner. 8: 87-96.
70. Hassager, C., Eastell, R., Christiansen, C. et al. (1992a) Effect of menolongitudinal pause and hormone replacement therapy on urinary excretion of pyridinium cross-links: a and cross-sectional study. Clin. Endocrinol. 37: 45-50.
71. Seibel, M. J., Cosman, F., Ratcliffe, A. et al. (1993) Urinary hydroxy-pyridinium cross-links of collagen as markers of bone resorption and oestrogen efficacy in post-menopausal osteoporosis. J. Bone Miner. Res. 9: 881-889.
72. Schlemer, A., Hassager, C., Christiansen, C. et al. (1994b) Urinary excretion of pyridinium cross-links in healthy women: the long-term effects of menopause and oestrogen/progesterone therapy. Clin. Endocrinol. 40: 777-782.
73. Garnero, P., Chapuy, M. C., Delmas, P. D. et al. (1996) Increased bone turnover in late post- menopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11: 337-349.
74. Beardsworth, L. J., Eyre, D. R. & Dickson, I. R. (1990) Changes with age in the excretion of lysyl and hydroxylysylpyridinoline: two new markers of bone collagen turnover. J. Bone Miner. Res. 5: 671-676.
75. Eastell, R., Russell, R. G. G. & Reeve, J. (1990) Urinary collagen cross-links are highly correlated with radioisotopic measurements of bone resorption. In: Christiansen C. & Overgaard, K. eds, Osteoporosis. Copenhagen: Osteopress Aps, pp. 469-470.
76. Delmas, P. D., Schlemmer, A., Gineyts, E. & Christiansen, C. (1991b) Urinary excretion of pyridinoline cross-links correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J. Clin. Endocrinol. Metab. 6: 639-644.
77. Eastell, R., Assiri, A. M. A., Russell, R. G. G. et al. (1993) Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporosis Int. 3: 255-260.
78. Assiri, A. M. A., Blumsohn, A., Eastell, R. et al. (1994) Bone-specific biochemical markers of turnover in patients with Paget's disease of bone. Bone 15: 735.
79. Seibel, M. J., Ratcliffe, A., Robins, S. P. et al. (1991) Urinary hydroxypyridinium cross-links of collagen in hyperparathyroidism. J. Clin. Endocrinol. Metab. 74: 481-486.
80. Harvey, R. D., Duncan, A., Robins, S. P. et al. (1991) Measurement of bone collagen degradation in hyperperathyroidism and during thyroxin replacement therapy using pyridinium cross- links as specific urinary markers. J. Clin. Endocrinol. Metab. 72: 1189-1194.
81. Gough, A. K., Eastell, R. & Emery, P. (1994) Excretion of pyridinium cross-links correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann. Rheum. Dis. 53: 14-17.
82. McLaren, Hordon, L. D., Robins, S. P. et al. (1992) Urinary excretion of pyridinium cross-links of collagen in patients with osteoporosis and the effects of bone fracture. Ann. Rheum. Dis. 51:648-651.
83. Hannon, R. A., Blumsohn, A., Eastell, et al. (1995) The effect of fracture healing on biochemical markers of bone turnover. Bone 16: 691.
84. Black, D., Duncan, A. & Robins, S. P. (1988) Quantitative analysis of the pyridinium cross-links of collagen in urine ion-paired reversed-phase high-performance liquid chromatography. Anal. Biochem. 169: 197-203.
85. Pratt, D. A., Daniloff, Y., Duncan, A. et al. (1992) Automated analysis of hydroxypyridinium cross-links of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography. Ann. Biochem. 207: 168-175.
86. Fujimoto, D., Suzuki, M., Inour, T. et al. (1983) Analysis of pyridinoline, a crosslinking compound of collagen fibers in human urine. J. Biochem. 94: 1133-1136.
87. James, I. T., Perret, D. & Thompson, P. W. (1990) Rapid assay for hard tissue collagen crosslinks using isocratic ion-pair reversed-phase chromatography. J. Chromatogr. 525: 43-57.
88. Robins, S. P. (1982) An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochem. J. 207: 617-620.
89. James, I. T., Crowley, C. & Perret, D. (1993) Assay of pyridinium cross-links in serum using narrow bore ion-paired reversed phase high-performance liquid chromatography. J. Chromatogr. 612: 41-84.
90. Abbiatti, G., Rigoldi, M., Mussini, E. et al. (1994) Determination of pyridinium cross-links in plasma and serum by high-performance chromatography. J. Chromatogr. 656: 303-310.
91. Ibrahim, S., Mojiminiti, S. & Barron, J. (1996) High performance liquid Chromatographic determination of pyridinium cross-links in serum, urine and dialysate in chronic renal failure. Ann. Clin. Biochem. 33: 31-35.
92. Colwell, A. & Eastell, R. (1996) The renal clearance of free and conjugated pyridinium cross- links of collagen. J. Bone Miner. Res. (in press).
93. Paterson, C. R., Robins, S. P. & Cuschieri, A. (1991) Pyridinium cross-links as markers of bone resorption in patients with breast cancer. Br. J. Cancer 64: 884-886.
94. Lipton, A., Demers, L., Seyedin, S. et al. (1993) Increased urinary excretion of pyridinium cross-links in cancer patients. Clin. Chem. 39: 614-618.
95. Sano, M., Kushida, K., Takahashi, M. et al. (1994) Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastases. Br. J. Cancer 70: 701-703.
96. Takeuchi, S. & Yoshida, K. (1994) Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness in patients with prostate cancer with bone metastases. Jpn. J. Urol. 85: 1521-1527.
97. Assiri, A. M. A., Blumsohn, A., Eastell, R. et al. (1995) Bone-specific biochemical markers of turnover in multiple myeloma. Bone 16: 690.
98. Taube, T., Tammela, T. L. J., Elomaa, I. et al. (1994) The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo controlled study. Eur. J. Cancer 30: 751-758.
99. Urwin, G. H., Percival, R. C., Kanis, J. A. et al. (1985) Generalised increase in bone resorption in carcinoma of prostate. Br. J. Urol. 57: 721-723.
100. Downey, S, Walls, J., Eastell, R. et al. (1994) Pyridinoline excretion can monitor bone metastases in breast cancer. Breast Cancer Res. Treat. 32 (Suppl. 1): 83.
101. Demers, L. M., Costa, L., Lipton, A. et al. (1995) Biochemical markers of bone turnover in patients with metastatic bone disease. Clin. Chem. 41: 1489-1494.
102. Li, F., Pitt, P. I., Moniz, C. et al. Biochemical markers of bone turnover in women with surgically treated carcinoma of the breast. E. J. Clin. Invest. 23: 566-571.
103. Walls, J., Ratcliffe, W. A., Assiri, A. et al. (1994a) Urinary pyridinolines identify bone resorption in humoral hypercalcaemia. Br. J. Surg. 81: 767.
104. Bundred, N. J., Ratcliffe, W. A., Ratcliffe, J. G. et al. (1991) Parathyroid hormone-related protein and hypercalcaemia in breast cancer. BMJ 303: 1506-1509.
105. Bertolini, D. R., Newdin, G. E., Mundy, G. R. et al. (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319: 516.
106. Sabatini, M., Boyce, B., Audfdemorte, T. et al. (1988) Infusions of recombinant human interleukin-1 cause hypercalcaemia in normal mice. Proc. Natl. Acad. Sci. 85: 5235-5239.
107. Yoneda, H., Nakai, M., Moriyama, K. et al. (1993) Neutralising antibodies to human interleukin-6 reverse hypercalcaemia associated with a human squamous carcinoma. Cancer Res. 53: 737-740.
108. Body, J. J., Dumon, J. C. & Delmas, P. D. (1994) Comparative evaluation of markers of bone resorption after a single dose of pamidronate in patients with breast cancer induced osteolysis. Bone Miner. 25 (Suppl. 1): S77.
109. Coleman, R. E., Houston, S., Rubens, R. D. et al. (1992) Preliminary results of the use of urinary excretion of pyridinium cross-links for monitoring metastatic bone disease. Br. J. Cancer 65: 766-768.
110. Walls, J., Ratcliffe, W. A., Assiri, A. et al. (1994b) Urinary cross-links: mechanisms of hypercalcaemia in women with breast cancer. Br. J. Surg. 81: 755.
111. Body, J. J. & Delmas, P. D. (1992) Urinary pyridinium cross-links as markers of bone resorption in tumour-associated hypercalcaemia. J. Clin. Endocrinol. Metab. 74: 471-475.
112. Pecherstorfer, M., Hermann, Z., Thiebaud, D. et al. (1996) Randomised phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcaemia of malignancy. J. Clin. Oncol. 14: 268-276.
113. Kenny, A., Prestwood, K. M., Raisz, G. et al. (1995) The short-term effects of tamoxifen on bone turnover in older women. J. Clin. Endocrinol. Metab. 80: 3287-3291.
114. Walls, J., Bundred, N. & Howell, A. (1995) Hypercalcaemia and bone resorption in malignancy. Clin. Orthop. Relat. Res. 312: 51-63.
115. Ikeda, I., Miura, T. & Kondo, I. (1996) Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br. J. Urol. 77: 102-106.
116. Wada, S., Katayama, Y., Nagata, N. et al. (1993) Changes of bone metabolic markers in patients with bone metastases: clinical significance in assessing bone response to chemotherapy. Int. Med. 32: 611-618.
117. Lipton, A., Hortobagyi, G., Reitsma, et al. (1995) Markers of bone resorption in patients treated with pamidronate. Bone 17: 615.
118. Bonde, M., Qvist, P., Christiansen, C. et al. (1994a) Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 40: 2022-2025.
119. Hanson, D. A., Weis, M. A. E., Bollen, A. M. et al. (1992) A specific immunoassay for monitoring human bone resorption: quantification of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7: 1251-1258.
120. Bonde, M., Qvist, P., Christiansen, C. et al. (1995a) Effect of bisphosphonates therapies (pamidronate and ibandronate) on the excretion of degradation products of the C-telopeptides of type I collagen measured by a radioimmunoassay (Crosslaps RIA). Bone 17: 609.
121. Bonde, M., Qvist, P., Christiansen, C. et al. (1994b) Crosslaps ELISA PLUS - an immunoassay for the measurement of degradation products of type I collagen in serum. J. Bone Miner. Res. 9 (Suppl. 1): S274.
122. Garnero, P., Rendu, E. S., Delmas, P. et al. (1995a) Decreased bone turnover in oral contraceptive users. Bone 16: 499-503.
123. Xue, Y., Dong, J. Y., Tan, X. M. et al. (1995) Study on a specific bone resorption marker, urinary crosslinked collagen peptide. J. Bone Miner. Res. 10 (Suppl. 1): S403.
124. Shary, J., Bell, L., Mallinak, N. et al. (1995) Comparison of three types of urine collections for measurement of urinary n-telopeptide of type I collagen. J. Bone Miner. Res. 10 (Suppl. 1): S183.
125. Bonde, M., Qvist, P., Christiansen, C. et al. (1995b) Applications of an enzyme immunoassay for a new marker of bone resorption (Crosslaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80: 864-868.
126. Gibson, N. S., Axelrod, D., Raisz, L. et al. (1995) Comparison of bone marker assays in different post-menopausal states. Calcif. Tissue Int. 56: 260.
127. Garnero, P., Gineyts, E., Delmas, P. D. et al. (1994a) Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrin. Metab. 79: 780-785.
128. Garnero, P., Shih, W., Delmas, P. et al. (1994b) Comparison of new biochemical markers of bone turnover in late post-menopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79: 1693-1700.
129. Gernero, P., Christiansen, C., Delmas, P. et al. (1995b) Different effects of bisphosphonate and oestrogen therapy on free and peptide bound cross-links excretion. J. Bone Miner. Res. 10: 641-649.
130. Rosen, H. N., Clemens, J. D., Greenspan, S. L. et al. (1994a) Specificity of urinary excretion of crosslinked N-telopeptides of type I collagen as a marker of bone turnover. Calcif. Tissue Int. 54: 26-29.
131. Gertz, B. J., Shao, P., Eyre, D. R. et al. (1994) Monitoring bone resorption in early post- menopausal women by an immunoassay for cross-linked collagen peptides in urine. J. Bone Miner. Res. 9: 135-142.
132. Blumsohn, A., Naylor, K. E., Eastell, R. et al. (1995b) Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin. Chem. 41: 1592-1598.
133. Pedrazzoni, M., Basini, G., Passeri, M. et al. (1995) Acute effects of bisphosphonates on new and traditional markers of bone resorption. Calcif. Tissue Int. 57: 25-29.
134. Yamamoto, I., Morita, R., Fujimoto R. et al. (1995) Clinical studies using measurement of N- telopeptides of type I collagen (NTx) in patients with bone metastases. Comparison with bone scintigraphy and other metabolic markers. Kakuigaku 32: 501-510.
135. Vinholes, J., Eastell, R. & Coleman, R. (1996c) Double-blind randomised trial of pamidionate for the palliative treatment of metastatic bone disease. J. Natl. Cancer Inst (in press).
136. Abbiatti, G., Rigoldi, M., Castiglioni, C. et al. (1993) Monitoring of free and total pyridinoline and deoxypyridinoline in healthy volunteers: sample relationships between 24-h and fasting early morning urine concentrations. Bone Miner. 21: 9-19.
137. Kamel, S., Desmet, G., Sebert, J. L. et al. (1995) Multiple molecular forms of pyridinolines cross-links excreted in human urine evaluated by Chromatographic and immunoassays. J. Bone Miner. Res. 10: 1385-1392.
138. Seyedin, S. M., Rosen, H. N., Zuk, R. F. et al. (1993) Immunoassay for urinary pyridinoline: the new marker of bone resorption. J. Bone Miner. Res. 8: 635-641.
139. Delmas, P. D., Garnero, P., Marchand, F. et al. (1993) Immunoassay of pyridinoline cross-link excretion in normal adults and in Paget's disease. J. Bone Miner. Res. 8: 643-648.
140. Seibel, M. J., Nicol, P. & Robins, S. P. (1994) Urinary hydroxypyridinium cross-links of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study. J. Bone Miner. Res. 9: 1433-1440.
141. Prestwood, K. M., Pilbeam, C. C., Delmas, P. D. et al. (1994) The short-term effects of conjugated oestrogen on bone turnover in older women. J. Clin. Endocrinol. Metab. 79: 366-371.
142. Arbault, P., Seguin, P., Delmas, P. D. et al. (1995) Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases, Bone 16: 461-467.
143. Withhold, W., Vosberg, H., Reinauer, H. et al. (1995a) Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases. Clin. Biochem. 28: 511-517.
144. Urena, P., Ferreira, A., Kung, V. T. et al. (1995) Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J. Bone Miner. Res. 10: 932-993.
145. Alvarez, L., Bedini, J. L., Ballesta, A. et al. (1995) Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J. Bone Miner. Res. 10: 458-465.
146. Body, J. J., Dumon, J. C., Lumen, M. A. et al. (1995b) Biochemical dose-response of pamidronate in post-menopausal osteoporosis - evaluation of new markers of bone resorption. Calcif. Tissue Int. 56: 481.
147. Van Daele, P. L., Seibel, M. J. et al. (1996) Case-control analysis of bone resorption markers, disability and hip fracture: the Rotterdam study. BMJ 312: 482-483.
148. Takahashi, S., Aiba, K. & Ogata, E. (1995) Efficiency of biochemical markers of bone metabolism to detect bone metastases of breast cancer. J. Bone Miner. Res. 10 (Suppl. 1): S399.
149. Withold, W., Vosberg, H., Reinauer, H. et al. (1995b) Simultaneous assessment of type I collagen synthesis and degradation for detection of bone metastases. Eur. J. Clin. Chem. Clin. Biochem. 33: 479-485.
150. Nguyen-Pamart, M., Bonneterre, J. & Hecquet, B. (1995) Urinary excretion of deoxypyridinoline in patients with breast cancer. Anticancer Res. 15: 1601-1604.
151. Koizumi, M., Aiba, K., Ogata, E. et al. (1995) Bone metabolic markers in bone metastases. J. Canc. Res. Clin. Oncol. 121: 542-548.
152. Nakayama, K., Fujimoto, S., Hata, K. et al. (1996) Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcaemia. J. Clin. Endocrinol. Metab. 81: 607-611.
153. Risteli, J., Elomaa, I., Risteli, L. et al. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new marker of bone resorption. Clin. Chem. 39: 635-640.
154. Kylmala, T., Ristelli, J., Elomaa, I. et al. (1993) Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. Eur. J. Cancer 29A: 821-825.
155. Rudnicki, M., Jensen, L. T. & Iversen, P. (1995) Collagen derived serum markers in carcinoma of the prostate. Scand. J. Urol. Nephrol. 29: 317-321.
156. Abildgaard, N., Nielsen, J. L., Heickendorff, L. et al. (1994) Connective tissue components in serum in multiple myeloma: analysis of propeptides of type I and III procollagens, type I collagen telopeptide, and hyaluronan. Am. J. Haematol. 46: 173-178.
157. Kylmala, T., Ristelli, J., Elomaa, I. et al. (1995) Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br. J. Cancer 71: 1061-1064.
158. Elomaa, I., Risteli, L., Risteli, J. et al. (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator of multiple myeloma. Br. J. Cancer 66: 337-341.
159. Blomqvist, C., Sarna, S., Elomaa, I. et al. (1966) Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br. J. Cancer 73: 1074-1079.
160. Carlson, K., Simonsson, S. & Ljunghall, S. (1994) Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. Calcif. Tissue Int. 55: 408-411.
161. Kelley, P. J., Biggs, J. C., Eisman, J. A. et al. (1990) Reduced bone mineral density in men and women with allogenic bone marrow transplantation. Transplantation 50: 251-262.
162. Segrest, J. P. (1982) Urinary metabolites of collagen. Meth. Enzymol. 82: 398-401.
163. Segrest, J. P. & Cunningham, I. W. (1979) Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism. J. Clin. Invest. 49: 1497-1509.
164. Moro, L., Rovis, L., Monfardini, S. et al. (1990) High predictivity of galactosyl-hydroxylysine in urine as an indicator of bone metastases from breast cancer. Clin. Chem. 36: 772-774.
165. AI-Dehaimi, A. W., Russell, R. G. & Eastell, R. (1993) Factors affecting the assay of urinary galactosyl-hydroxylysine as marker of bone resorption. J. Bone Miner. Res. 8: S150.
166. AI-Dehaimi, A. W., Blumsohn, A., Eastell, R. et al (1995) Serum galactosyl-hydroxylysine as marker of bone resorption. Bone 16: S217.
167. Moro, L., Talamini, R., Bernard, B. et al. (1993) Biochemical markers for detecting bone metastases in patients with breast cancer. Clin. Chem. 39: 131-134.
168. Farrugia, W. & Melick, R. A. (1986) Metabolism of osteocalcin. Calcif. Tissue In. 39: 234-238.
169. Delmas, P. D., Mann, K. G., Riggs, B. L. et al. (1983) Effect of renal function on plasma levels of bone Gla protein. J. Clin. Endocrinol. Metab. 57: 1028-1030.
170. Vanderschueren, D., Gevers, G. & Dequeker, J. (1990) Sex- and age-related changes in bone and serum osteocalcin. Calcif. Tissue Int. 46: 179-182.
171. Thomsen, K., Charles, P., Mosekilde, L. et al. (1989) Seasonal variation of serum bone GLA protein. Scand. J. Clin. Lab. Invest. 49: 605-611.
172. Vanderschueren, D., Gevers, G., Dequeker, J. et al. (1991) Seasonal variation in bone metabolism in young healthy subjects. Calcif. Tissue Int. 49: 84-89.
173. Rosen, C. J., Morrison, A., Hunter, S. J. et al. (1994b) Elderly women in northern England exhibit seasonal changes in bone mineral density and calciotropic hormones. Bone Miner. 25: 83-92.
174. Lian, J., Reit, B. & Glimcher, M. (1982) Concentrations of osteocalcin and phosphoprotein as a function of mineral content and age in cortical bone. Calcif. Tissue Int. 34: S82-S827.
175. Brown, J. P., Delmas, P. D., Meunier, P. J. et al. (1984) Serum bone-gla protein: a specific marker for bone formation in post-menopausal osteoporosis. Lancet 1: 1091-1093.
176. Eastell, R., Mann, K. G., Riggs, BL. et al. (1988) Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J. Clin. Endocrinol. Metab. 67: 741-748.
177. Masters, P. W., Jones, R. G., Cooney, J. M. et al. (1994) Commercial assays for serum osteocalcin give clinically discordant results. Clin. Chem. 40: 358-363.
178. Garnero, P., Seguin, P. & Delmas, P. (1994c) Characterisation of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 9: 255-264.
179. Blumsohn, A., Hannon, R. & Eastell, R. (1995c) Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin. Chem. 41: 318-319.
180. Delmas, P. D., Chapuy, M. C., Meunier, P. J. et al. (1986a) Serum bone Gla protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif. Tissue Int. 38: 60-61.
181. Duda, R. J., Mann, K. G., Riggs, B. L. et al. (1988) Concurrent assays of circulating bone Gla- protein and bone alkaline phosphatase: effects of age, sex and metabolic disease. J. Clin. Endocrinol. Metab. 66: 951-957.
182. Nielsen, H. K., Thomesn, K., Eriksen, E. F. et al. (1988) The effects of glucorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase, and vitamin D metabolites in normal subjects. Bone Miner. 4: 105.
183. Godschalk, M. F. & Downs, R. W. (1988) Effect of short-term glucorticoids on serum osteocalcin in healthy young men. J. Bone Miner. Res. 3: 113-115.
184. Coleman, R. E., Fogelman, I., Rubens, R. et al. (1988c) Osteocalcin: a potential marker of metastatic bone disease and response to treatment. Eur. J. Clin. Oncol. 7: 1211-1217.
185. Pietschmann, Zielinski, C. & Woloszczuk, W. (1989) Serum osteocalcin levels in breast cancer patients. J. Cancer Res. Clin. Oncol. 115: 456-458.
186. Arai, Y., Takeuchi, H., Yoshida, O. et al. (1992) Osteocalcin: Is it a useful marker of bone metastases and response to treatment in advanced prostate cancer? Prostate 20: 169-177.
187. Marcelini, M., Mainiero, G, Cantiani, R. et al. (1992) Serum osteocalcin in monitoring bone metastases in advanced prostate cancer. Eur. Urol. 21 (Suppl. 1): 102-104.
188. Burlina, A., Zaninotto, M., Plebani, M. et al. (1994) Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase. Clin. Chim. Acta 226: 151-158.
189. Conte, N., Legovini, P., Foscolo, G. et al. (1991) Clodronate treatment increases serum osteocalcin in normocalcaemic osteolytic bone metastases. Oncology 48: 54-57.
190. Neri, B., Ludovici, M., Pacini, P. et al. (1992) Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anti-Cancer Drugs 3: 87-90.
191. Francini, G., Paffeti, P., Gennari, C. et al. (1992) Treatment of bone metastases with dichloromethylene bisphosphonate. J. Clin. Oncol. 4: 591-598.
192. Clarke, NW, McClure, J., George, N. J. R. et al. (1991). Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br. J. Cancer 63: 420-423.
193. Delmas, P. D., Chapuy, M. C., Meunier, P. J. et al. (1986b) Serum bone γ-carboxyglutamic acid- containing protein in primary hyperparathyroidism and in patients with hypercalcaemia. J. Clin. Invest. 7: 985-991.
194. Dumon JC, Cleeren A, Body JJ, et al. (1994) Comparative evaluation of various markers of bone formation in tumour-induced hypercalcaemia. Bone Miner. 25 (Suppl. 1), S78.
195. Body, J. J., Cleeren, A. & Pot, M. (1986b) Serum osteocalcin (BGP) in tumour-associated hypercalcaemia. J. Bone Miner. Res. 1: 523-527.
196. Berruti, A., Dogliotti, L., Angelli, A. et al. (1995) Serial evaluation of bone formation markers in breast cancer patients with bone metastases. Effect of chemotherapy with or without pamidronate. Bone 17: 607.
197. Berenson, J., Lichtenstein, A., Knight, R. et al. for the Myeloma Aredia Study Group. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Engl. J. Med. 334: 488-493.
198. Walton, R. J., Preston, C., Russell, R. G. et al. (1975) An estimate of the turnover rate of bone derived plasma alkaline phosphatase in Paget's disease of bone. Clin. Chim. Acta 63: 227-229.
199. Charles, P., Poser, J. W., Jensen, F. T. et al. (1985) Estimation of bone turnover evaluated by Ca kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J. Clin. Invest. 76: 2254-2258.
200. Brixen, K., Eriksen, E. F. & Charles, P. (1989) Efficacy of wheat-germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralization rate: comparison to serum total alkaline phosphatase and serum bone gla-protein. Calcif. Tissue Int. 44: 93-98.
201. Nielsen, H. K., Brixen, K. & Mosekilde, L. (1990) Diurnal rhythm in serum activity of wheatgerm lectin-precipitable alkaline phosphatase: temporal relationships with the diurnal rhythm of osteocalcin. Scand. J. Clin. Lab. Invest. 50: 851-685.
202. Rosalki, S. B. & Foo, A. Y. (1984) Two new methods for separating and quantifying bone and liver phosphatase isoenzymes in plasma. Clin. Chem. 30: 1182-1186.
203. Moss, D. W. & Whitby, L. G. (1975) A simplified heat-inactivation method for investigating alkaline phosphatase isoenzymes in serum. Clin. Chem. Acta 61: 63-71.
204. Shephard, M. D. S. & Peak, M. J. (1986) Quantitative method for determining serum alkaline phosphatase isoenzyme activity: guanidine hydrochloride, a new reagent for selectively inhibiting major serum isoenzymes of alkaline phosphatase. J. Clin. Pathol. 39: 1025-1030.
205. Peaston, R. T. & Cooper, J. (1986) Affinity electrophoresis of alkaline phosphatase isoenzymes. Clin. Chem. 32: 235-236.
206. Hill, C. S. & Wolfert, R. L. (1989) The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin. Chim. Acta 186: 315-320.
207. Gomez, B., Haugen, S., Ardakani, S, et al. (1994) Measurement of bone specific alkaline phosphatase activity in serum using a monoclonal antibody. J. Bone Miner. Res. 9: 348S.
208. Minisola, S., Perugia, G., Mazzuoli, G. et al. (1987) Biochemical picture accompanying sclerotic bone metastases of prostatic origin. Br. J. Urol. 60: 443-446.
209. Reale, M. G., Santini, D., Frati, L. et al. (1994) Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer. Int. J. Biol. Markers 10: 42-46.
210. Francini, G., Paffeti, P., Leone, V. et al. (1990) Comparison between CEA, TPA, CA 15.3, hydroxyproline, alkaline phosphatase, whole body retention of 99 mTc MDP in the follow-up of bone metastases in breast cancer. Int. J. Biol. Markers 5: 65-72.
211. Plebani, M., Zaninotto, M., Sciacovelli, L. et al. (1996) New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin. Biochem. 29: 67-72.
212. Van Hoof, VO., Oosteron, A. T., Broe, M. E. et al. (1992) Alkaline phosphatase isoenzyme patterns in malignant disease. Clin. Chem. 38: 2546-2551.
213. Cooper, E. H., Hancock, A. K., Laurence, V. et al. (1992) Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases. Biomed. Pharmacother. 46: 31-36.
214. Hortobagyi, G., Libshitz, H. & Seabold, J. E. (1984) Osseous metastases from breast cancer. Cancer 53: 577-582.
215. Berruti, A., Roncari, A., Dogliotti, L. et al. (1993) Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases. Oncology 50: 218-221.
216. Mackintosh, J., Simes, J., Pearson, B. et al. (1990) Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the 'SAP' flare. Br. J. Urol. 66: 88-93.
217. Zaninotto, M., Rubin, D., Plebani, M. et al. (1995) Serum bone alkaline phosphatase in the follow-up of skeletal metastases. Anticancer Res. 15: 2223-2228.
218. Smedsrod, B., Melkko, J., Ristelli, J. et al. (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 271: 345-350.
219. Savolainen, E. R., Leo, M. A., Lieber, C. S. et al. (1984) Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcohol Clin. Exp. Res. 8: 384-389.
220. Hassager, C., Ristelli, J., Christiansen, C. et al. (1992b) Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 7: 1307-1311.
221. Melkko, J., Ristelli, J., Ristelli, L. et al. (1990) Radioimmunoassay of the carboxyterminal propeptide of type I procollagen. Clin. Chem. 36: 1328-1332.
222. Taubman, M. B., Goldberg, B. & Scherr, C. J. (1974) Radioimmunoassay for human procollagen. Science 186: 1115-1117.
223. Ebeling, P. R., Peterson, J. M. & Riggs, B. L. (1992) Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 7: 1243-1250.
224. Hassager, C., Fabri-Mabbeli, G., Christiansen, C. et al. (1993) The effect of the menopause and hormone replacement therapy on serum carboxyterminal of propeptide of type I collagen. Osteoporosis Int. 3: 50-52.
225. Piovesan, A., Berruti, A. & Angelli, A. (1994) Serum levels of carboxyterminal propeptide of type I procollagen in cancer patients with osteoblastic and osteolytic metastases. Int. J. Biol. Markers 9: 243-246.
226. Santi, I., Monti, M., Cunieti, E. et al. (1995) Serum levels of procollagen type I carboxyterminal extension peptide in cancer patients with bone metastases. Int. J. Biol. Markers 10: 107-112.
227. Francini, G., Gonelli, S., Camporeale, A. et al. (1993) Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol. Biomarkers Prev. 2: 125-129.
228. Guerrieri, P., Parisi, S., Vettori, P. G. et al. (1994) Bone formation markers and pain palliation in bone metastases treated with strontium-89. Am. J. Clin. Oncol. 17: 77-79.
229. Risteli, J., Niemi, S, Risteli L. et al. (1988) Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen. Clin. Chem. 34: 715-718.
230. Kaupilla, A., Risteli, J., Risteli, L. et al. (1989) Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer. Cancer Res. 49: 1885-1889.
231. Edelstyn, G. A., Gillespie, P. J. & Grebbel, F. S. (1967) The radiological demonstration of osseous metastases: experimental observations. Clin. Radiol. 18: 158-162.
232. Thrall, J. H. & Ellis, B. (1987) Skeletal metastases. Radiol. Clinic North America 25: 1155-1170.
233. Galasko, C. S. B. & Doyle, F. H. (1972) The detection of skeletal metastases from mammary cancer. A regional comparison between radiography and scintigraphy. Clin. Radiol. 23: 295-297.
234. Muindi, J., Coombes, R. C., Golding, S. et al. (1983) The role of computed tomography in the detection of bone metastases in breast cancer. Br. J. Radiol. 56: 233-236.
235. Raffi, M., Firoonia, H., Golimbu, C. & Beranhbaum, E. (1986) CT of skeletal metastases. Semin Ultrasound CT MR 7: 371-379.
236. Daffner, R. H., Lupetin, A. R., Dash, N. et al. (1986) MRI and the detection of malignant infiltration of bone marrow. Am. J. Roentgenol. 146: 353-358.
237. Avrahami, E., Tadmor, R., Hadar, H. et al. (1989) MRI demonstration of spinal metastases in patients with normal radiographs, CT and radionuclide bone scans. J. Comput. Assist. Tomog. 133: 598-602.
238. Frank, J. A., Ling, A. & Patronas, N. J. (1990) Detection of malignant bone tumours: MR imaging vs scintigraphy. Am. J. Radiol. 155: 1043-1048.
239. Algra, P. R., Bloem, J. L., Verboom, L. J. et al. (1991) Detection of vertebral metastases: comparison between MR imaging and bone scintigraphy. Radiographics 11: 219-232.
240. Jones, A. L., Williams, M. P., Powles, T. J. et al. (1990) Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer. Br. J. Cancer 62: 296-298.
241. Hayward, J. L., Carbone, P. P., Heuson, J. J., Kumaoka, S., Segaloff, A. & Rubens, R. (1977) Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289-1294.
242. Libshitz, H. & Hortobagyi, G. (1981) Radiographic evaluation of therapeutic response in bony metastases of breast cancer. Skeletal. Radiol. 7: 159-165.
243. Scher, H. I. & Yagoda, A. (1987) Bone metastases: pathogenesis, treatment and rational for use of resorption inhibitors. Am. J. Med. 82: 6-28.
244. Galasko, C. S. B. (1994) Diagnosis of skeletal metastases and assessment of response to treatment. In: Diel, I. J., Kauffman, N., Bastert, G. eds, Metastatic Bone Disease. Berlin: Springer Verlag, pp. 93-107.
245. Coleman, R. E. & Rubens, R. (1985) Breast cancer and bone metastases. Cancer Treat. Rev. 12: 251-270.
246. Howell, A., Mackintosh, J., Jones, M. et al. (1988) The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur. J. Cancer 24: 1567-1572.
247. Coleman, R. E., Mashiter, G., Whitaker, K. B., Moss, D. W., Rubens, R. D. & Fogelman, I. (1988d) The bone scan flare predicts successful systemic therapy for bone metastases. J. Nucl. Med. 29: 1354-1359.
248. Vandermark, R. M., Shpall, E. J. & Affronti, M. L. (1992) Bone metastases from breast cancer: value of CT bone windows. J. Comput. Assist. Tomogr. 16: 608-614.